Fig. 7: Transduction of human iPSC-derived neurons by AAV1.eGFP and AAV-DB-3.mTFP1.
From: Optimized AAV capsids for basal ganglia diseases show robust potency and distribution
A Direct fluorescence of AAV1.eGFP and AAV-DB-3.mTFP1 in iPSC-derived excitatory neurons 10 days post-transduction with indicated MOIs. Nuclei were stained with Hoechst 33258. Scale bars, 50 µm. B Quantitation of percent transduction of AAV-DB3.mTFP relative to AAV1.eGFP. Five or more images were quantified per dose. 3857 and 3333 cells were counted in the AAV1 and AAV-DB-3 treatment groups respectively. Data are represented as mean +/− SEM. Results were significant by 2-way ANOVA for AAV treatment (54.43% of total variation, F (1, 26) = 68.03, p < 0.0001) and dose (24.77% of total variation, F (2, 26) = 15.48, p < 0.0001). C Quantitative PCR for transgene expression. All samples were normalized to GAPDH and are presented relative to AAV1.eGFP at the 1 E3 MOI. Data are represented as mean +/− SEM with points representing 3 biological replicates performed in triplicate. Results were significant by 2-way ANOVA for AAV treatment (40.66% of total variation, F (1, 14) = 22.77, p = 0.0003) and dose (34.35% of total variation, F (2, 14) = 9.617, p = 0.0024). Source data are provided in the Source Data file.
